-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bentracimab in Bleeding And Clotting Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bentracimab in Bleeding And Clotting Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bentracimab in Bleeding And Clotting Disorders Drug Details: Bentracimab (PB-2452...
-
Thematic Analysis
State of the Biopharmaceutical Industry in 2024 – Thematic Intelligence
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you in: Examining the current attitudes of business leaders toward the emerging trends impacting the biopharmaceutical industry in the next 12 months. Benchmarking the impact of major themes on the biopharmaceutical industry in 2024, including emerging technologies, regulatory trends, macroeconomic trends, and industry trends. Identifying the most impactful anticipated regulatory approvals and drug launches in the industry in 2024, learning about top-selling drugs (2023 vs 2024), and obtaining...
-
Thematic Analysis
Synthetic Biology – Thematic Intelligence
Synthetic Biology Thematic Report Overview Synthetic biology is commonly abbreviated to synbio. It involves the manipulation of genetic material to enhance specific characteristics or, conversely, stifle them. The ability to perform this manipulation quickly, precisely, and at a low cost has the potential to impact numerous sectors. From developing environmentally friendly luxury materials to novel cancer therapeutics and even the use of DNA as a new form of data storage, the forthcoming field of synbio unlocks several new realms of...
-
Sector Analysis
Artificial Intelligence in Pharma – Impact, Trends, Key Players and Top AI Drugs
This report investigates the impacts and development of Artificial Intelligence within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Thematic Analysis
Digital Transformation and Emerging Technologies in the Healthcare Industry – Thematic Intelligence
Explore trends and insights from the following data in our ‘Digital Transformation and Emerging Technologies in the Healthcare Industry’ report: Stay up to date on the scope, challenges, and essentials for the digital transformation within the healthcare industry. Explore how innovations are transforming the healthcare industry and what impact on the sector these technologies will have soon. Develop and design your corporate strategies through an in-house expert analysis of the key factors of digital transformation and emerging technology in the healthcare sector....
-
Analyst Opinions
New Prescription – Generative Artificial Intelligence (AI) Meets Healthcare
Generative Artificial Intelligence (AI) in Healthcare Report Overview Generative AI can accelerate pharmaceutical drug discovery, enhance clinical trials and drug approval, optimize manufacturing and the supply chain, boost sales and marketing, and improve healthcare delivery as well as patient outcomes. For instance, pharmaceutical drug discovery can be enhanced by automating target identification and optimizing lead generation, significantly reducing the time and resources required in drug development. Furthermore, Generative AI enhances clinical trials by facilitating the eligibility screening process, enrollment, predicting outcomes,...
-
Company Profile
AbSci Corp – Company Profile
AbSci Corp (AbSci) operates as a biotechnology company which develops protein production technologies. The company offers SoluPro, a genetically engineered semi-oxidizing cytoplasm and a dual inducible promoter system that enables scalable production of antibodies, antibody fragments and other soluble recombinant proteins. AbSci's technology accelerates drug discovery timelines, increases manufacturing efficiencies and drastically reduces costs for the biopharmaceutical industry. The company provides its proteins and antibodies in the areas of cancer, hormone, autoimmune and blood disorder therapies. It collaborates with pharmaceutical...
Add to Basket -
Analyst Opinions
Text-to-X – How ChatGPT and Generative AI can Transform the Future of Business
Accessing in-depth insights from the ‘Text-to-X – How ChatGPT and Generative AI can Transform the Future of Business’ report will offer you: Innovation examples by each use case segment of various sectors to present key trends. Real-world innovation use cases and examples related to the implementation of ChatGPT and generative AI by companies across sectors. How generative AI-enabled innovations are developing use cases that are helping enterprises across different sectors. How is the report different from other reports in the market?...
-
Analyst Opinions
Engineering Microorganisms into Powerful Micromachines: Can Synthetic Biology Foster Bio-Revolution?​
Achieving global goals such as mass-scale food production and sustainable low-cost manufacturing methods is the need of the hour. Synthetic Biology (SynBio) is a field of science that has grown over the last two decades to emerge as a mature area in biological engineering with its potential to reduce the costs of biological production methods and improve the global food supply. It also can be crucial to create patient-centric drugs and promote precision medicine for better health outcomes. SynBio is...